Lexicon Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Lexicon Pharmaceuticals şirketinin toplam hissedar öz sermayesi $178.5M ve toplam borcu $99.9M olup, bu da borç-öz sermaye oranını 56% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $321.1M ve $142.6M dir.

Anahtar bilgiler

56.0%

Borç/özkaynak oranı

US$99.90m

Borç

Faiz karşılama oranı	n/a
Nakit	US$258.37m
Eşitlik	US$178.51m
Toplam yükümlülükler	US$142.61m
Toplam varlıklar	US$321.12m

Son finansal sağlık güncellemeleri

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Recent updates

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Oct 16

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Aug 03

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Aug 08

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: LXRX 'nin kısa vadeli varlıkları ( $268.6M ) kısa vadeli yükümlülüklerini ( $36.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: LXRX şirketinin kısa vadeli varlıkları ( $268.6M ) uzun vadeli yükümlülüklerini ( $106.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: LXRX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: LXRX 'nin borç/öz sermaye oranı son 5 yılda 148.8% seviyesinden 56% seviyesine düştü.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: LXRX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: LXRX un, serbest nakit akışı her yıl % 26 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/26 01:20
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Lexicon Pharmaceuticals, Inc. 15 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Yigal Nochomovitz	Citigroup Inc
Kevin Kedra	G. Research, LLC
Joseph Pantginis	H.C. Wainwright & Co.

Lexicon Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Recent updates

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces Receipt of Complete Response Letter for Zynquista™ (sotagliflozin)

Lexicon Pharmaceuticals, Inc. Announces Completion of Enrollment in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)

Price target decreased by 13% to US$4.68

Lexicon Pharmaceuticals, Inc. Announces Board Changes

Consensus revenue estimates decrease by 24%

New major risk - Financial position

Price target increased by 16% to US$6.25

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. Publishes Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 16% to US$5.40

Lexicon Pharmaceuticals, Inc. Announces Outcome of FDA Advisory Committee for Zynquista (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease

Consensus revenue estimates increase by 33%

Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes

Lexicon Pharmaceuticals, Inc. to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress

Lexicon Pharmaceuticals, Inc. Appoints Kristen L. Alexander as Its Principal Financial Officer

Lexicon Pharmaceuticals, Inc. Announces Post-Hoc Analysis of Phase 3 Data from the SCORED Clinical Trial

Consensus revenue estimates decrease by 41%

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success

Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Lexicon Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Lexicon Pharmaceuticals, Inc. Receives PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission

Lexicon Pharmaceuticals, Inc. Publishes New Data Highlights Potential Cost-Savings of INPEFA®? (sotagliflozin) for Heart Failure

High number of new directors

Lexicon Pharmaceuticals, Inc. Announces Appointment of Mike Exton, Ph.D. as Chief Executive Officer

Lexicon Pharmaceuticals, Inc. Announces CEO Changes

Lexicon Pharmaceuticals, Inc. Announces That Data From it's RELIEF-DPN 1 Phase 2 Study of LX9211 Published in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association

Price target increased by 13% to US$6.20

Lexicon Pharmaceuticals: Blue Sky Aplenty, Revenue Not So Much

New major risk - Shareholder dilution

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Lexicon Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 02, 2024

Lexicon Pharmaceuticals, Inc. Announces Resignation of Lonnel Coats as Chief Executive Officer, Effective from July 7, 2024

Lexicon Pharmaceuticals, Inc., Annual General Meeting, May 10, 2024

Consensus revenue estimates decrease by 44%, EPS upgraded

Lexicon Pharmaceuticals, Inc. announced that it has received $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC, Artal International Management Sa, Artal International SCA, Artal Group S.A.

New major risk - Share price stability

Lexicon Pharmaceuticals, Inc. Announces New Post Hoc Analysis of Intandem3 Study Demonstrates Improvements in Glycemic Control with Sotagliflozin Treatment in Patients with Type 1 Diabetes and Chronic Kidney Disease

Lexicon Pharmaceuticals: Moving To Maximize The Value Of Its Core Asset

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Lexicon Pharmaceuticals, Inc. announced that it expects to receive $249.99995 million in funding from Braidwell LP, Great Point Partners, LLC and other investors.

CEO & Director exercised options and sold US$161k worth of stock

Consensus revenue estimates fall by 54%

Lexicon Pharmaceuticals Putting The Pieces Together, But Much Is Left To Do

Lexicon Pharmaceuticals, Inc. Provides Business and Pipeline Update At 42nd Annual J.P. Morgan Healthcare Conference

Consensus revenue estimates decrease by 12%

Price target decreased by 7.2% to US$5.15

Lexicon Pharmaceuticals, Inc. Enrolls First Patient in Phase 2B Progress Study of Lx9211 in Diabetic Peripheral Neuropathic Pain

Independent Director recently bought US$202k worth of stock

Consensus revenue estimates decrease by 31%, EPS upgraded

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 30% to US$7.50

Lexicon Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Lexicon Pharmaceuticals, Inc. Appoints Lisa DeFrancesco as Head of Investor Relations and Corporate Strategy, Effective November 13, 2023

Lexicon Pharmaceuticals, Inc. Announces Data from Two Studies Demonstrating Positive Financial Impact of Inpefa (Sotagliflozin) to Be Presented At the Academy of Managed Care Pharmacy Nexus 2023 National Meeting

Independent Chairman of the Board recently bought US$1.1m worth of stock

Lexicon Pharmaceuticals, Inc. Announces the Retirement of Alan S. Nies from Board of Directors, Effective October 26, 2023

New minor risk - Share price stability

Lexicon Pharmaceuticals, Inc. Receives Preferred Formulary Status with Express Scripts for Medicare Patients

Lexicon Pharmaceuticals, Inc. to Present Study Results Relating to Sotagliflozin and Lx9211 At the 59Th Annual Meeting of the European Association for the Study of Diabetes

Consensus EPS estimates fall by 18%

Lexicon Pharmaceuticals, Inc. Announces Published Analysis of Sotagliflozin Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure

Here's Why Lexicon Pharmaceuticals (NASDAQ:LXRX) Can Manage Its Debt Despite Losing Money

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Lexicon Pharmaceuticals, Inc. Elects Diane E. Sullivan to Its Board of Directors

Lexicon Pharmaceuticals, Inc. Announces Resignation of Frank P. Palantoni from Board of Directors, Effective July 27, 2023

CEO & Director recently bought US$92k worth of stock

Lexicon Pharmaceuticals, Inc. Presents Study Results Relating to LX9211 and INPEFA (Sotagliflozin) At the American Diabetes Association’s 83rd Scientific Sessions

Lexicon Pharmaceuticals, Inc. Announces FDA Approval of INPEFA (sotagliflozin) for Treatment of Heart Failure

Lexicon Pharmaceuticals, Inc. announced that it has received $72.21513 million in funding from The Invus Group, LLC

Lexicon Pharmaceuticals, Inc. announced that it has received $62.795767 million in funding from The Invus Group, LLC